2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alan P. Z. Skarbnik, discusses ongoing research with PI3K inhibitors in follicular lymphoma.
Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses ongoing research with PI3K inhibitors in follicular lymphoma.
Among ongoing research efforts in follicular lymphoma is the development of novel PI3K inhibitors, says Skarbnik.
To date, 3 PI3K inhibitors are approved for patients with B-cell malignancies, including idelalisib (Zydelig), copanlisib (Aliqopa), and duvelisib (Copiktra), Skarbnik explains.
The safety profiles of these agents vary, but common adverse include gastrointestinal toxicity, inflammatory diarrhea, and rash, Skarbnik says.
As such, the goal of second-generation PI3K inhibitors, such as duvelisib, is to inhibit disease proliferation and minimizeimmune-related toxicities by targeting the delta and gamma portions of PI3K, Skarbnik concludes.